Age | Lesion Very likely Basal cell carcinoma | Lesion Diameter Largest | Location of lesion Trunk | Location of lesion Extremities Proximal Wrist | Location of lesion Extremities Proximal Ankle
Item
patients 18 years or older that are determined by an investigator to have a lesion that is highly likely to be a bcc, less than or equal to 1.0cm in largest diameter, based on clinical examination located in the trunk or extremities, proximal to the wrist and ankles
boolean
C0001779 (UMLS CUI [1])
C0221198 (UMLS CUI [2,1])
C3840799 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C0221198 (UMLS CUI [3,1])
C1301886 (UMLS CUI [3,2])
C0443228 (UMLS CUI [3,3])
C2184261 (UMLS CUI [4,1])
C0460005 (UMLS CUI [4,2])
C2184261 (UMLS CUI [5,1])
C0015385 (UMLS CUI [5,2])
C0205107 (UMLS CUI [5,3])
C0043262 (UMLS CUI [5,4])
C2184261 (UMLS CUI [6,1])
C0015385 (UMLS CUI [6,2])
C0205107 (UMLS CUI [6,3])
C0003086 (UMLS CUI [6,4])
Informed Consent
Item
subject is able to give informed consent
boolean
C0021430 (UMLS CUI [1])
Follow-up Duration Commitment
Item
subject is able to commit to 6 month follow up visit
boolean
C3274571 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
Basal cell carcinoma Diameter Axis Any
Item
bcc > 1cm in diameter on any one axis.
boolean
C0007117 (UMLS CUI [1,1])
C1301886 (UMLS CUI [1,2])
C1522496 (UMLS CUI [1,3])
C1552551 (UMLS CUI [1,4])
Therapeutic immunosuppression
Item
immunosuppressed patients
boolean
C0021079 (UMLS CUI [1])
Neutropenia
Item
subjects with neutropenia
boolean
C0027947 (UMLS CUI [1])
Organ Transplantation
Item
organ transplant patients
boolean
C0029216 (UMLS CUI [1])
Life Expectancy
Item
subjects with a life expectancy less than year
boolean
C0023671 (UMLS CUI [1])
Immunosuppressive Agents | Prednisone Dosage | Azathioprine | mycophenolate mofetil | Cyclosporine | Tacrolimus Oral Product | TNF-alpha inhibitor | ustekinumab | rituximab
Item
patients taking immunosuppressive medications, including prednisone at a dose of 10mg or greater with an expected duration greater than 4 weeks, azathioprine, mycophenolate mofetil, cyclosporine, oral tacrolimus, any tumor necrosis factor (tnf)-alpha inhibitor, ustekinumab, rituximab, or any other medication in the judgement of the investigator could results in clinically meaningful immunosuppression of the subject
boolean
C0021081 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0004482 (UMLS CUI [3])
C0209368 (UMLS CUI [4])
C0010592 (UMLS CUI [5])
C1273163 (UMLS CUI [6])
C1562242 (UMLS CUI [7])
C1608841 (UMLS CUI [8])
C0393022 (UMLS CUI [9])
Basal cell carcinoma infiltrative Clinical examination | Morpheic basal cell carcinoma Clinical examination
Item
basal cell carcinomas that have infiltrative or morpheaform characteristics based on clinical examination
boolean
C1304298 (UMLS CUI [1,1])
C1456356 (UMLS CUI [1,2])
C0555191 (UMLS CUI [2,1])
C1456356 (UMLS CUI [2,2])
Informed Consent Unable
Item
subjects unable to provide informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Follow-up Duration Commitment Unable
Item
subjects unable to commit to 6 month follow up
boolean
C3274571 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])